References
  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16 :178–222.
  2. Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia.Circulation 2012;125 :2447–53.
  3. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gammaglobulin dose but independent of salicylate dose. J Pediatr1997;131 :888–93.
  4. Newburger JW, Sleeper LA, McCrindle BW, et al.Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med2007;356 :663–75.
  5. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gammaglobulin treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J1998;17 :1144–8.
  6. Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.Pediatr Infect Dis J 2008;27 :155–60.
  7. Furukawa T, Kishiro M, Akimoto K, et al.Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.Arch Dis Child 2008;93 :142–6.
  8. Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123 :657–9.
  9. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. Circulation2004;110 :2747–71.
  10. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr2006; 149 :336–41.
  11. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous Gamma globulin treatment failure in Kawasaki disease. Pediatrics2000;105 :E78.
  12. Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128 :146–9.
  13. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:ascientific statement for health professionals from the American Heart Association.Circulation 2017;135 :e1–e73.
  14. Carlin JB, Doyle LW. Statistics for clinicians. 7: Sample size. J Paediatr Child Health 2002; 38 :300-304.
  15. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics2004;114 (6): 1708–33.
  16. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.Circulation 2006;113 :2606–12.
  17. Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128 :146–9.
  18. Egami K, Muta H, Ishii M,et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149 :237–40.
  19. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol2006;33 :803–9.
  20. Sonoda K, Mori M, Hokosaki T, et al. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 2014;164 : 1128–32.
  21. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics2000;105 :E78.
  22. Cohen S, Tacke CE, Straver B, et al. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis 2012; 71 : 2059–61.
  23. Furusho K, Kamiya T, Nakano H,et al. High dose intravenous gammaglobulin for Kawasaki disease.Lancet 1984;2 :1055–8.
  24. Kato H, Koike S, Yokoyama T.Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics1979;63 :175–9.
  25. Teraguchi M, Ogino KY, Taniuchi S, et al. Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: aprospective study.PediatrCardiol2013;34 (4):959–63.
  26. Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr1999;135 :465–9.
  27. Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013;99 :76–82.
  28. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93 :142–6.
  29. MiuraM, Ohki H, YoshibaS, et al. Adverse effects of methyl-prednisolone pulse therapy in refractory Kawasaki disease.Arch Dis Child 2005;90 (10): 1096–7.
  30. Zhang YL, Du ZD, Fu PP, et al. Curative effect observation of different doses of intravenous gamma globulin or methylprednisolone in children with unresponsive Kawasaki disease. Chinese Journal of Evidence-Based Pediatrics 2013;8 (3): 220–3.